What Plecanatide is
Plecanatide is a guanylate cyclase-C agonist peptide medicine used in approved constipation-related GI contexts.
Plecanatide is grouped under Approved / Clinical on PeptideFactCheck because it shows another real peptide-drug lane in gastroenterology, not just hormone and metabolism drugs.
The useful starting point is to separate the molecule itself from the internet story around it. It shows another real peptide-drug lane in gastroenterology, not just hormone and metabolism drugs.
Why people keep looking it up
It shows another real peptide-drug lane in gastroenterology, not just hormone and metabolism drugs.
Plecanatide is a guanylate cyclase-C agonist peptide medicine used in approved constipation-related GI contexts.
Plecanatide tends to stay in the conversation because it touches a familiar public theme: guanylate cyclase-c, gi motility, and intestinal secretion. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Approved GI peptide drug with direct human evidence.
Human trials and approved labeling support specific uses.
Mechanistic support aligns with intestinal fluid-secretion and motility biology.
Why this page carries the current tier: Approved GI peptide drug with direct human evidence.
The current seed trail for Plecanatide is pulling from 1 labels source, 1 regulatory source, and 1 literature source.
Safety, limits, and regulatory context
Approved GI drugs still need indication-specific reading rather than broad digestive-health extrapolation.
FDA-approved plecanatide products exist for specific indications.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Plecanatide. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Plecanatide is CID 70693500. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 70693500
- Formula
- C65H104N18O26S4
- Molecular weight
- 1681.9
- InChIKey
- NSPHQWLKCGGCQR-DLJDZFDSSA-N
Matched synonyms include PLECANATIDE, Trulance, 467426-54-6, Guanilib, plecanatida, 7IK8Z952OK, SP-304 (SYNERGY), DTXSID60196933.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Plecanatide returns 14 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Plecanatide returns 130 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Label and regulatory records
For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.
- Brand names
- Trulance Immediate release
- Generic names
- PLECANATIDE
- Routes
- ORAL
- Application numbers
- NDA208745
Indications and usage. 1 INDICATIONS AND USAGE TRULANCE is indicated in adults for the treatment of: chronic idiopathic constipation (CIC). irritable bowel syndrome with constipation (IBS-C). TRULANCE is a guanylate cyclase-C agonist indicated in adults for treatment of: chronic idiopathic constipation (CIC). ( 1 ) irritable bowel syndrome with constipation (IBS-C). ( 1 )
Warnings and cautions. 5 WARNINGS AND PRECAUTIONS Diarrhea: Patients may experience severe diarrhea. If severe diarrhea occurs, suspend dosing and rehydrate the patient. ( 5.2 ) 5.1 Risk of Serious Dehydration in Pediatric Patients TRULANCE is contraindicated in patients less than 6 years of age. The safety and effectiveness of TRULANCE in patients less than 18 years of age have not been established. In young juvenile mice (human age equi...
Contraindications. 4 CONTRAINDICATIONS TRULANCE is contraindicated in: Patients less than 6 years of age due to the risk of serious dehydration [see Warnings and Precautions (5.1) , Use in Specific Populations (8.4) ] . Patients with known or suspected mechanical gastrointestinal obstruction. Patients less than 6 years of age due to the risk of serious dehydration. ( 4 , 5.1 , 8.4 ) Patients with known or suspected mechanical gastroin...
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.